Foresite Capital

Foresite Capital
Industry Venture capital, growth equity
Founded 2011
Founder Jim Tananbaum, CEO
Website www.foresitecapital.com

Foresite Capital is an American venture capital and growth equity firm.[1][2] The company has offices in San Francisco and New York. As of May 2017, the company had raised three funds, Foresite Capital Fund I, II and III.[1]

History

Foresite Capital was founded in 2011 by Jim Tananbaum, co-founder of Theravance,[3][4] who became CEO of the company.[5]

Foresite Capital raised its $100 million Fund I in 2013.[6][7] Foresite has invested in companies such as Epizyme,[1] Intarcia Therapeutics,[8][9] Aerie Pharmaceuticals,[10] Muse Bio[11] and Universal American,[5] Foresite has funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016.[12][13] In April 2014,[5] Foresite closed Foresite Capital Fund II, a $300 million fund.[14] Foresite Capital Fund III, a $450 million fund, was closed in July 2015.[14]

References

  1. 1 2 3 David Holley (29 July 2015). "Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund". Xconomy. Retrieved 20 May 2017.
  2. ↑ Brian Gormley (31 January 2013). "Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund". Wall Street Journal. Retrieved 20 May 2017.
  3. ↑ Damian Garde (29 July 2015). "Foresite Capital reloads with a $450M biotech venture fund". Fierce Biotech. Retrieved 20 May 2017.
  4. ↑ "Foresite Capital raises $100M to invest in late-stage healthcare companies". San Francisco Business Times. 31 January 2013. Retrieved 20 May 2017.
  5. 1 2 3 Eric Blattberg (1 April 2014). "Health care venture firm Foresite Capital closes $300M fund". Venture Beat. Retrieved 20 May 2017.
  6. ↑ Ben Fidler (6 November 2013). "Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today". Xconomy. Retrieved 20 May 2017.
  7. ↑ Luke Timmerman (31 January 2013). "Foresite Capital Closes $100M Fund for Late-Stage Biotechs". Xconomy. Retrieved 20 May 2017.
  8. ↑ Dan Primack (15 September 2016). "Diabetes 'Unicorn' Raises Final VC Round Before IPO". Fortune. Retrieved 20 May 2017.
  9. ↑ "Here's who stands to gain from Intarcia's success with a type 2 diabetes pump". Boston Business Journal. 2 October 2014. Retrieved 20 May 2017.
  10. ↑ Ed Lin (14 October 2016). "Aerie Stock Hits Record High, Holder Sells $2 Million". Barrons. Retrieved 20 May 2017.
  11. ↑ "Muse Bio Closes $23M Series B Financing Round". Genome Web. Retrieved 20 May 2017.
  12. ↑ Nick Paul Taylor (21 March 2016). "10X Genomics scoops another $55M to fuel commercialization of long-read tech". Fierce Biotech. Retrieved 20 May 2017.
  13. ↑ Alex Lash (12 January 2015). "10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade". Xconomy. Retrieved 20 May 2017.
  14. 1 2 Damian Gards (1 April 2014). "Foresite banks $300M to bet on late-stage biotechs". Fierce Biotech. Retrieved 20 May 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.